All In Biotech

Drug Trial Radar · NCT07813767

THE ROLE OF PANCREATIC STONE PROTEIN (PSP) AND PSP-GUIDED EARLY MEROPENEM TREATMENT TO MITIGATE SEPSIS RISK AT THE EMERGENCY DEPARTMENT: THE PROMISE DOUBLE BLIND, PHASE III, RANDOMIZED CONTROLLED CLINICAL TRIAL

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 398 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

398

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Sep 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Hellenic Institute for the Study of SepsisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to demonstrate the clinical benefit of early intervention with meropenem in adult patients of both sexes with suspected infection and risk of sepsis. The primary objective is to evaluate the clinical benefit of a protein called Pancreatic Stone Protein (PSP), which, if elevated, indicates that patient may be at increased risk of developing sepsis. The secondary objectives are to investigate the impact of early antibiotic treatment with meropenem on progression to sepsis, survival and mortality. Researchers will compare meropenem to a placebo (a look-alike substance that contains no drug). Participants will: * Take a single dose of meropenem or a placebo * Be evaluated at designated timepoints post administration until their discharge and, also, on days 28 and 90 post administration, respectively.

Conditions

  • Sepsis

Interventions

  • Meropenem InfusionDrug

    There is no other intervention in this clinical study and participation in another clinical study is an exclusion criterion.

  • Sodium Chloride (NaCl) 0.9 %Drug

    There is no other intervention in this clinical study and participation in another clinical study is an exclusion criterion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 28-day mortalityTime frame: 28 days after administration of the study intervention

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Emergency Medicine, G.Gennimatas Athens General Hospital

    Athens, Attica, Greece · Recruiting

  • Department of Emergency Medicine, ATTIKON University General Hospital

    Athens, Attica, Greece · Recruiting

  • Department of Emergency Medicine, Aghios Panteleimon Nikaia General Hospital

    Athens, Attica, Greece · Recruiting

  • Department of Emergency Medicine, Tzaneion Piraeus General Hospital

    Piraeus, Attica, Greece · Recruiting

  • Department of Emergency Medicine, Ioannina University General Hospital

    Ioannina, Ioannina, Greece · Recruiting

  • Department of Internal Medicine, Syros General Hospital

    Ermoupoli, Syros, Cyclades, Greece · Recruiting

  • Department of Emergency Medicine, AHEPA Thessaloniki University General Hospital

    Thessaloniki, Thessaloniki, Greece · Recruiting

  • Department of Emergency Medicine, G. Papanikolaou Thessaloniki General Hospital

    Thessaloniki, Thessaloniki, Greece · Recruiting

  • Department of Emergency Medicine, Koutlibaneio & Triantafylleio General Hospital of Larissa

    Larissa, Thessaly, Greece · Recruiting

  • 1st Department of Internal Medicine, Thriasio Eleusis General Hospital

    Elefsina, West Attica, Greece · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.